• Press Releases.png

    Press Releases

OmniComm Systems, Inc. Announces Major New Release of TrialMaster® EDC

December 30, 2013

CONTACT :

Dr Kuno van der Post
OmniComm Systems, Inc.
954-473-1254
kvanderpost@omnicomm.com

Download Press Release

Innovation and Interoperability is the Focus of Version 4.2

Fort Lauderdale, FL, December 30, 2013 – OmniComm Systems, Inc (OTC: OMCM), today announced the production availability of Version 4.2 of TrialMaster, its flagship product for Electronic Data Capture (EDC). This new release includes hundreds of innovative productivity and functionality enhancements, including additional features for auto-redaction for faster and more efficient centralized and riskedbased monitoring, and major new features for exporting data utilizing OmniComm’s award winning Export Utility

“This is going to be a significant release for the industry.” said Kuno van der Post, SVP of Business Development, “The industry is changing rapidly with new regulations and guidance being released by the FDA. OmniComm has set itself apart by releasing new technology that not only accommodates these changes, but allows our customers to capitalize on the benefits from them. Moreover, our significant investment in R&D is paying off with our all in-house development team delivering this significant new release within the promised timeframe and budget.”

Within three years, companies will be required by the FDA to provide their final datasets in Study Data Tabulation Model (STDM) format. TrialMaster 4.2 has automated the mapping and transposition tools required to perform this work. “The return on investment for our customers is very compelling” said Keith Howells, SVP of Product Development. “For example, our fully automated SDTM data export utility means that within 24 hours of database lock you can have your data in SDTM format. This saves our clients significant amounts of time and money per study.”

TrialMaster 4.2 has also been engineered for high performance and stability. It is built on the latest Microsoft technology stack and supports the most modern and fastest browsers, including Internet Explorer 11, Firefox and Chrome. This means the product can support the largest and most complex clinical trials, while retaining its legendary ease of use.

“The focus of this release is clearly on innovation, but a significant amount of work has also gone into this release to ensure stability and optimal performance. There are a large number of stability and productivity enhancements that may not make headlines, but offer enhanced value to our customers. A complete new interface offering double data entry has been added to go along with the game changing new features,” said Stephen Johnson, OmniComm’s President and Chief Operating Officer. “Companies looking for a robust and full-featured EDC product will appreciate the best in class technology in TrialMaster 4.2.”

About OmniComm Systems

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.